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In the mid-19th century, pathologists observed that some 
malignant tumors have features that are similar to those 
of the embryonic tissues (extensive proliferation and 
diﬀ  er  entiation).  Th  is led pathologists to suggest that 
activation of quiescent, undiﬀ  erentiated embryonic cells 
may be the root cause of cancer [1,2]. However, it was not 
until 1961 that Till and McCulloch [3] were able to 
provide the deﬁ   nitive proof that adult tissues are 
maintained by stem cells. Later, Bonnet and Dick [4] were 
able to show that, similarly to the normal adult tissues, 
malignant tumors can be initiated and maintained by a 
rare-cell population with stem cell properties (cancer 
stem cells).  Th  ese observations suggest that a lack of 
knowledge about the unique biology of these cancer stem 
cells is the reason for the failure of the current cancer 
therapies. Moreover, they suggest that understanding the 
mechanisms that regulate the biology and function of the 
normal primitive cells will provide a framework to 
determine how alterations to these mecha  nisms can 
confer a cancer stem cell phenotype on these rare-cell 
populations.
Recent research eﬀ  orts have led to the isolation and 
molecular characterization of the normal human and 
mouse breast stem cells and progenitors [5-8]. Th  ese 
studies revealed that breast stem cells are estrogen 
receptor-negative (ER−) and therefore were thought to be 
the origin of the ER− basal-like breast tumors [9]. 
Currently, however, the nature of the cancer-initiating 
cells remains elusive. Cancer-initiating cells are referred 
to the normal cells in the adult tissues, including the stem 
cells and progenitors as well as the diﬀ  erentiated cells 
that can acquire enough mutations to transform into 
cancer stem cells. Th   erefore, cancer stem cells arise from 
cancer-initiating cells and are responsible for tumor 
recurrence (that is, proliferation and self-renewal 
potentials) and the tumor heterogeneity (that is, multi-
lineage diﬀ  erentiation potential).
To ascertain the nature of the cancer-initiating cells, 
Molyneux and colleagues [10] used a mouse model of 
breast cancer in which inactivating Brca1 mutation in p53
heterozygote mutant animals causes basal-like breast 
carcinoma. To identify the cancer-initiating cell popula-
tion, the authors induced an inactivating Brca1 mutation 
under the expression of Cre enzyme either in the ER−
luminal progenitors using beta-lactoglobulin promoter 
(Blg-CreBrca1f/fp53+/−) or in the stem cells and basal cells 
using the cytokeratin 14 promoter (K14-CreBrca1f/fp53+/−). 
Interestingly, the authors found that inactivation of 
Brca1 gene in the luminal progenitors, and not in the 
basal and stem cells, produced tumors that closely 
resembled the human BRCA1 mutant (basal-like) breast 
tumors as determined by immuno  histopathological 
studies. Despite this, the molecular characterization of 
18  Blg-CreBrca1f/fp53+/− and 3 K14-CreBrca1f/fp53+/−
tumors revealed that 16 out of the 21 tumors closely 
resembled the normal ER− luminal cells. However, when 
human breast cancer subtype classiﬁ  er gene sets (PAM50 
and Hu306) were used as predictors [11,12] to classify 
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tumors, the authors found that all tumors associated with 
the sporadic basal-like breast cancers. Th  is observation 
was conﬁ   rmed when the same mouse tumors were 
classiﬁ  ed using the gene expression proﬁ  le of a panel of 
53 grade-3 human breast cancers [13] and the NKI295 
tumor gene expression data set [14]. Interestingly, when 
comparing the histological features of the secondary and 
tertiary transplanted tumors, the authors found evidence 
of clonal selection. Th  is obser  vation suggests that ER− 
luminal progenitors, when harboring a Brca1 loss, can 
act as cancer-initiating cells, some of which can acquire a 
cancer stem cell phenotype and produce basal-like 
tumors. Th  is  ﬁ   nding is interesting since Lim and 
colleagues [15] reported the expansion of the luminal 
progenitors in the BRCA1 mutation carriers.
Th  e data described by Molyneux and colleagues [10] 
explore the relationship between the cancer-initiating 
cells, cancer stem cells, and the tumor phenotype. Th  eir 
data suggest that luminal progenitors, and not the breast 
stem cells, are the more likely sources of the cancer-
initiating cells that can lead to the generation of basal-like 
tumors. Th  is conclusion implicates the plasticity of the 
cancer-initiating cells as the most likely determinant of 
the tumor type, which may be diﬀ  erent than the cancer-
initiating cell phenotype.
Knowledge about the origin of cancer-initiating cells 
will enable the development of novel cancer preventative 
approaches. Such therapeutic measures will depend on 
the elucidation of the molecular mechanisms that regu-
late the proliferation, diﬀ   erentiation, and self-renewal 
capacities of the normal stem and progenitors cells. For 
example, it would be interesting to determine the precise 
role of Brca1 in the normal biology and functions of the 
ER− luminal progenitors and how its inactivation can 
cause these cells to develop basal-like cancers. Such 
know  ledge can lead to the development of therapies not 
based on the Brca1 gene itself but on the aﬀ  ected signal-
ing pathways. In addition, characterization of the basal-
like cancer-initiating cells can lead to the identiﬁ  cation of 
new diagnostic markers that will enable the detection of 
the breast tumors at a premalignant stage.
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